Abstract:Ye Liu, 1, &ast Lifan Zhang, 1– 4, &ast Yan Chen, 1, &ast Guiren Ruan, 1– 3 Yuchen Liu, 1 Shi Chen, 1 Lantian Xie, 1 Fengying Wu, 1 Xiaochun Shi, 1– 3 Xiaoqing Liu 1– 4 1 Division of Infectious Diseases, Department of Internal Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; 2 State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Beijing, People's Republic of China; 3 Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; 4 Clinical Epidemiology Unit, Peking Union Medical College, International Clinical Epidemiology Network, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiaochun Shi; Xiaoqing Liu, Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shuaifuyuan No. 1, Beijing, 100005, People's Republic of China, Email ; Background: The population with latent tuberculosis infection (LTBI) represents a potential pool of patients with active tuberculosis (ATB). T-SPOT.TB is an important test tool for screening LTBI. Owing to the large population of LTBI patients in China, it is necessary to identify a high-risk group for LTBI and enlarge tuberculosis preventive treatment (TPT) to reduce the incidence of ATB. Methods: Hospitalized patients with positive T-SPOT.TB results were recruited from January 2013 to December 2016. Patients with ATB were excluded. Basic information was collected and the development of ATBs was examined during follow-up. The life-table method was used to calculate cumulative incidence rates. Potential risk factors were analyzed through Cox regression analysis. Results: A total of 1680 patients with LTBI were recruited in the follow-up cohort, and 377 (22.44%) patients dropped out. With a median follow-up time of 81 months [interquartile range (IQR):61– 93], 19 of 1303 patients with LTBI developed ATB. The 1-year incidence of ATB was 614 per 100,000 individuals [95%confidence interval (95% CI):584– 644]. Over 5-year period, the cumulative incidence of ATB was 1496 per 100,000 [95% CI:1430– 1570], and the incidence density was 240 per 100,000 person-years[95% CI:144– 375]. In the Cox regression model, exposure of pulmonary tuberculosis (PTB) [adjusted hazard ratio (aHR)=10.557, 95% CI:2.273– 49.031], maximum daily dosage of glucocorticoids (GCs)≥ 50 mg/d (aHR=2.948, 95% CI:1.122– 7.748), leflunomide (LEF) treatment (aHR=8.572, 95% CI:2.222 − 33.070), anemia (aHR=2.565, 95% CI:1.015– 6.479) and T-SPOT.TB level≥ 300SFCs/10 6 PBMCs (aHR=4.195, 95% CI:1.365– 12.892) were independent risk factors for ATB development in LTBI patients. Conclusion: The incidence of ATB is significantly higher in hospitalized patients with LTBI than in the general population. The exposure history of PTB, maximum daily dosage of GCs≥ 50 mg/day, LEF treatment, anemia, and T-SPOT.TB level≥ 300SFCs/10 6 PBMCs, were the risk factors of tuberculosis reactivation. Hospitalized LTBI patients with the above factors may need TPT. Keywords: latent tuberculosis infection, active tuberculosis, incidence, risk factors Tuberculosis (TB) is an important infectious disease caused by Mycobacterium tuberculosis (MTB) that threatens human health. The Global TB Report 2022 noted that 10.6 million new TB cases were diagnosed in 2021, increasing of 3.6% over the previous year. China is one of the 30 high-burden countries. The WHO Health Organization estimated that China has 780,000 new TB patients, with an incidence of 55 per 100,000 in 2021. 1 The cumulative incidence of TB has reduced by only 11% from 2015 to 2021, far from the target of the Global End TB Strategy, which states that the incidence of TB should be reduced by 20% in 2020. 2,3 Latent tuberculosis infection (LTBI) is defined as a persistent immune response to stimulation by MTB antigens without active tuberculosis (ATB). LTBI has a 5% to 10% lifetime risk of progressing to ATB, mostly within 5 years of the initial infection. 4 There are two methods recommended by WHO for screening LTBI: tuberculin skin test (TST) and Interferon-γ release assays (IGRAs), including T-SPOT.TB. 5 The prevalence was estimated to be 20.3%, with nearly 300 million cases in China. 6 S -Abstract Truncated-

DISTRIBUTION OF ATHEROSCLEROSIS IN HUMAN DESCENDING THORACIC AORTA

Recurrent pulmonary tuberculosis after treatment success: a population-based retrospective study in China

Recurrent Tuberculosis in an Urban Area in China: Relapse or Exogenous Reinfection?

Epidemiology of recurrent pulmonary tuberculosis by bacteriological features of 100 million residents in China

Tuberculosis Recurrence over a 7-Year Follow-Up Period in Successfully Treated Patients in a Routine Program Setting in China: a Prospective Longitudinal Study

Relapse or Re-Infection, the Situation of Recurrent Tuberculosis in Eastern China

Epidemic Trends of Tuberculosis in China from 1990 to 2017: Evidence from the Global Burden of Disease Study.

Tuberculosis in China: A longitudinal predictive model of the general population and recommendations for achieving WHO goals.

Tuberculosis reinfection and relapse in eastern China: a prospective study using whole-genome sequencing

Changes in Incidence and Epidemiological Characteristics of Pulmonary Tuberculosis in Mainland China, 2005-2016

Treatment and recurrence on re-treatment tuberculosis patients: a randomized clinical trial and 7-year perspective cohort study in China

Spatial–temporal Analysis of Pulmonary Tuberculosis among Students in the Zhejiang Province of China from 2007–2020

Effect of Different Interventions for Latent Tuberculosis Infections in China: a Model-Based Study

Double-blind- evaluation of bromperidol versus haloperidol treatment in chronic psychotic patients.

Prevalence Trends of Latent Tuberculosis Infection at the Global, Regional, and Country Levels from 1990–2019

Investigation on the cause of recurrent tuberculosis in a rural area in China using whole-genome sequencing: A retrospective cohort study

Epidemiology and treatment outcomes of recurrent tuberculosis in Tanzania from 2018 to 2021 using the National TB dataset

A Modeling Study Recurrent Tuberculosis Towards End TB Strategy - China, 2025-2035

Patients at high risk of tuberculosis recurrence

Incidence and Risk Factors of Active Tuberculosis Among Hospitalized Patients with Latent Tuberculosis Infection in China: A Cohort Study

Trends in the Notification Rates and Treatment Outcome of Tuberculosis in Shandong Province, China, 2005–2021